Of warfarin in the prevention of thromboembolism in non-valvular atrial fibrillation in the safety evaluation.docVIP

 PAGE \* MERGEFORMAT 7 Of warfarin in the prevention of thromboembolism in non-valvular atrial fibrillation in the safety evaluation Keywords: non-valvular atrial fibrillation; of warfarin; Security With the aging of society, such as concurrent stroke have increased, therefore, for non-valvular atrial fibrillation complications of anticoagulant treatment embolism in clinical practice and more attention. Number of randomized controlled trials has confirmed that warfarin can reduce the risk of stroke and death [1]. In this paper, warfarin in the prevention of thromboembolism in non-valvular atrial fibrillation in to make an assessment of the safety. 1 Data and methods 1.1 General Information From January 2004 to January 2005 the clinical diagnosis of non-valvular atrial fibrillation, and those who need anticoagulation outpatient cases, 55 cases were randomly divided into two groups: warfarin group was 25 cases, of which 20 males and 5 females, with an average age (62.8 ± 12.7) years of age; control group: 30 patients received aspirin, of which 19 males, 11 females, mean age (63.2 ± 8.5) years of age. 1.2 Methods A case-control method to observe changes in patients with warfarin (INR target 2.0 to 2.5) in the treatment group (initial dose of 2.5mg / d) and received aspirin 150 mg / d in the control group 1 year. Follow-up and observation of clinical thromboembolic events and the body parts of any bleeding and other complications. Anticoagulant therapy monitoring, to start using the next day the first week of warfarin determination of INR, the first 2-12 weeks, weekly measurements 1 INR, 12 weeks after a second monthly monitoring INR. 1.3 Statistical analysis Data with mean ± standard deviation, said count data with the x2 test, P lt;0.05 for significant statistical significance. 2 Results Adjusted-dose warfarin therapy and aspirin 150 mg / d treatment, comparing the two groups during the